相似文献
1
Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment.
Oncoimmunology. 2016 Jul 29;5(9):e1216292. doi: 10.1080/2162402X.2016.1216292. eCollection 2016.
2
Anti-CD73 in cancer immunotherapy: awakening new opportunities.
Trends Cancer. 2016 Feb 1;2(2):95-109. doi: 10.1016/j.trecan.2016.01.003.
3
Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.
Purinergic Signal. 2016 Jun;12(2):303-12. doi: 10.1007/s11302-016-9505-8. Epub 2016 Feb 24.
4
CD73 as a potential opportunity for cancer immunotherapy.
Expert Opin Ther Targets. 2019 Feb;23(2):127-142. doi: 10.1080/14728222.2019.1559829. Epub 2018 Dec 26.
5
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
Ann Oncol. 2018 Apr 1;29(4):1056-1062. doi: 10.1093/annonc/mdx730.
6
Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Int J Cancer. 2018 Sep 15;143(6):1494-1504. doi: 10.1002/ijc.31534.
7
CD73, Tumor Plasticity and Immune Evasion in Solid Cancers.
Cancers (Basel). 2021 Jan 7;13(2):177. doi: 10.3390/cancers13020177.
8
Anti-CD73 therapy impairs tumor angiogenesis.
Int J Cancer. 2014 Mar 15;134(6):1466-73. doi: 10.1002/ijc.28456. Epub 2013 Sep 18.
9
CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.
J Clin Invest. 2020 Mar 2;130(3):1185-1198. doi: 10.1172/JCI128895.
10
CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth, angiogenesis, neovascularization, macrophage infiltration and metastasis.
Int J Biochem Cell Biol. 2015 Dec;69:1-10. doi: 10.1016/j.biocel.2015.10.003. Epub 2015 Oct 13.
引用本文的文献
1
CD73/adenosine dynamics in treatment-induced pneumonitis: balancing efficacy with risks of adverse events in combined radio-immunotherapies.
Front Cell Dev Biol. 2025 Jan 13;12:1471072. doi: 10.3389/fcell.2024.1471072. eCollection 2024.
2
Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches.
Cancer Control. 2024 Jan-Dec;31:10732748241290067. doi: 10.1177/10732748241290067.
3
synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy.
Nat Commun. 2024 Mar 1;15(1):1909. doi: 10.1038/s41467-024-46343-3.
4
Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics.
Clin Exp Med. 2023 Dec;23(8):4297-4322. doi: 10.1007/s10238-023-01201-2. Epub 2023 Oct 7.
5
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.
J Immunother Cancer. 2023 Sep;11(9). doi: 10.1136/jitc-2023-006837.
6
A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer.
Cancers (Basel). 2023 Jul 17;15(14):3651. doi: 10.3390/cancers15143651.
7
Natural killer cell immunotherapy in glioblastoma.
Discov Oncol. 2022 Oct 28;13(1):113. doi: 10.1007/s12672-022-00567-1.
8
SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC.
Front Immunol. 2022 Sep 9;13:982821. doi: 10.3389/fimmu.2022.982821. eCollection 2022.
9
Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors.
Elife. 2022 Jul 11;11:e73699. doi: 10.7554/eLife.73699.
10
Functional expression of CD73 on human natural killer cells.
Cancer Immunol Immunother. 2022 Dec;71(12):3043-3056. doi: 10.1007/s00262-022-03219-z. Epub 2022 May 25.
本文引用的文献
1
Targeting CD73 in the tumor microenvironment with MEDI9447.
Oncoimmunology. 2016 Jul 11;5(8):e1208875. doi: 10.1080/2162402X.2016.1208875. eCollection 2016 Aug.
2
Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.
Cancer Cell. 2016 Jul 11;30(1):147-160. doi: 10.1016/j.ccell.2016.05.016.
3
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Immunity. 2016 Jun 21;44(6):1255-69. doi: 10.1016/j.immuni.2016.06.001.
4
Anti-CD73 in cancer immunotherapy: awakening new opportunities.
Trends Cancer. 2016 Feb 1;2(2):95-109. doi: 10.1016/j.trecan.2016.01.003.
5
Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.
MAbs. 2016;8(3):454-67. doi: 10.1080/19420862.2016.1143182. Epub 2016 Feb 8.
6
CD73-adenosine: a next-generation target in immuno-oncology.
Immunotherapy. 2016 Feb;8(2):145-63. doi: 10.2217/imt.15.106. Epub 2016 Jan 25.
7
Tumor microenvironment: a new treatment target for cancer.
ISRN Biochem. 2014 Apr 10;2014:351959. doi: 10.1155/2014/351959. eCollection 2014.
8
Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression.
Cell Stem Cell. 2014 Jun 5;14(6):810-23. doi: 10.1016/j.stem.2014.04.014.
9
Immunity, inflammation and cancer: a leading role for adenosine.
Nat Rev Cancer. 2013 Dec;13(12):842-57. doi: 10.1038/nrc3613. Epub 2013 Nov 14.
10
The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine.
Cancer Res. 1997 Jul 1;57(13):2602-5.
Zotero 插件